Researchers conducted a retrospective cohort study of 34,248 women diagnosed with locoregional breast cancer who received ...

—Melissa McShane, MD, Assistant Professor, and Associate Program Director of the Hematology/Oncology Fellowship Training Program at Fox Chase Cancer Center describes the clues to HER2 ...

Radiopharm Theranostics Limited targets oncology with radiotherapeutics like Lu-RAD204 for NSCLC. Key 2025 data signals ...

The TKI zongertinib is currently being reviewed by the FDA for a potential approval for patients with HER2 mutation–positive ...

Triple negative breast cancer accounts for 15% of cases but causes a disproportionate number of deaths. Learn about symptoms ...

When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.

Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.

Vepdegestrant is a novel proteolysis targeting chimera protein degrader designed to target and degrade the estrogen receptor.

Shanghai Henlius Biotech announced that the FDA has granted Orphan Drug Designation for HLX22, an anti-HER2 monoclonal ...

Patients with recurrent/metastatic HER2-positive breast cancer experienced durable response and manageable safety from ...

Despite better overall prognoses, slow-growing breast cancer subtypes are associated with a higher mortality risk when ...